Sinopia Biosciences
Sinopia Biosciences is a pre-clinical biotech that uses its LEADS® platform — combining metabolomics, multi-omics data, and proprietary deep learning foundation models — to discover first-in-class therapeutics, with lead candidate SB-0110 entering Phase 1 trials for Parkinson's disease and additional programs in oral mucositis and oncology.
- Company typePrivate
- Founded2014
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Sinopia Biosciences does
Sinopia Biosciences is a privately held, pre-clinical biotechnology company founded in 2014 and headquartered at JLABS San Diego that has built the LEADS® (LEarn And DiScover) platform, a drug discovery engine combining high-throughput metabolomics, multi-omics data, proprietary deep learning foundation models, and network analyses to identify novel therapeutic targets and compounds. The platform is anchored on what Sinopia describes as the largest metabolomics dataset characterizing a small-molecule library and integrates metabolomics, genomics, and proteomics to predict therapeutic response and disease biology with greater sensitivity than upstream-biomolecule-only approaches. The company's internal pipeline is led by SB-0110, a first-in-class positive allosteric modulator of PKA-II for Parkinson's disease and levodopa-induced dyskinesia, which is advancing into Phase 1 clinical trials, with a second program in oral mucositis funded by NIDCR and a third oncology effort funded by NCI.
Sinopia generates revenue through non-dilutive grant funding from multiple NIH institutes (NIGMS, NINDS, NIDCR, NHLBI, NCI) and the Michael J. Fox Foundation, with cumulative NIH and MJFF funding exceeding $14M and an additional Ono Pharmaceutical target-discovery collaboration announced in March 2026 adding research funding, upfront payments, and milestone eligibility. The company has not yet commercialized any product, has no recurring software or services revenue, and operates with a headcount of 1–10 employees. Its IP estate includes 14 issued or allowed patents worldwide, including a composition-of-matter patent for SB-0110 issued in the US in January 2026 and parallel grants in Japan, China, Taiwan, and Mexico.
The leadership team combines academic systems biology pedigree with operational drug-development experience: co-founder Bernhard Palsson (700+ publications, 40+ patents, NAE member), CTO Aarash Bordbar (PI on $14M in grants, 13 patents), and CEO Iman Famili (16 patents, prior roles at Intrexon, Genomatica, GT Life Sciences). The board includes Executive Chair Arthur Suckow, who previously founded DTx Pharma and sold it to Novartis for $1B, and Abhay Joshi, former COO of Revance Therapeutics. The company has been an NVIDIA Inception member since 2019 and reports no venture capital or private equity funding disclosed to date.
Sinopia Biosciences firmographics
Firmographics- Name
- Sinopia Biosciences
- Legal name
- Sinopia Biosciences, Inc.
- Website
- https://sinopiabio.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sinopia Biosciences is a pre-clinical biotech that uses its LEADS® platform — combining metabolomics, multi-omics data, and proprietary deep learning foundation models — to discover first-in-class therapeutics, with lead candidate SB-0110 entering Phase 1 trials for Parkinson's disease and additional programs in oral mucositis and oncology.
- Ownership category
- akta.pro rank
Sinopia Biosciences industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Sinopia Biosciences is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sinopia Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Grant Funding (NIH): Sinopia Biosciences generates non-dilutive funding through multiple SBIR and other grants from the National Institutes of Health and its institutes (NIGMS, NINDS, NIDCR, NCI, NHLBI). These grants fund platform development and specific therapeutic programs.
- Strategic Partnerships and Collaborations: Sinopia receives research funding, upfront payments, and is eligible for future milestones through partnerships with pharmaceutical companies such as Ono Pharmaceutical for target discovery collaborations.
- Future Therapeutic Development: The company is advancing multiple first-in-class programs with high unmet need toward clinical development, with the lead program SB-0110 for Parkinson's disease progressing toward IND-enabling studies and clinical trials.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Sinopia Biosciences product offering
Product offeringCore offering
Sinopia Biosciences operates a proprietary drug-discovery platform called LEADS (LEarn And DiScover) that integrates high-throughput metabolomics data, AI/machine-learning foundation models engineered for omics, network analyses, and disease models to identify novel therapeutic targets and advance small-molecule drug candidates. Its most advanced program, SB-0110, is in clinical development for Parkinson's disease, with additional research programs spanning oral mucositis, oncology, rare blood disorders (platelet production), and rare metabolic diseases. The company monetizes this capability primarily through grant-funded research and milestone-bearing collaborations with biopharmaceutical partners such as Ono Pharmaceutical.
Product overview
Sinopia Biosciences operates as a single-platform biotechnology company centered on its proprietary LEADS® (LEarn And DiScover) drug discovery platform. The company leverages this AI/ML-driven omics platform to discover first-in-class therapeutics, with its lead development candidate SB-0110 for Parkinson's disease. The LEADS platform integrates high-throughput metabolomics data, deep learning foundation models, and network biology analyses to identify novel therapeutic targets and compounds. All therapeutic programs are discovered and developed internally through this platform.
Differentiator
Problem solved
Functional benefit
Brands
- LEADS®: LEarn And DiScover - Proprietary drug discovery platform combining high-throughput omics data, AI/machine learning, and network analyses for data-driven drug discovery.
Products and services
- LEADS Drug Discovery Platform Proprietary AI/omics drug-discovery platform integrating high-throughput metabolomics, machine-learning foundation models built for omics data, network analyses, and disease models to identify novel therapeutic targets and small-molecule candidates; serves as the company's primary internal discovery engine and the basis of its partnership/collaboration offerings.
- SB-0110 — Parkinson's disease lead program Lead small-molecule clinical-stage therapeutic candidate of Sinopia Biosciences, in development for Parkinson's disease; serves as the flagship asset validating the LEADS platform and is the focus of ongoing clinical and translational activity.
- Target-Discovery Partnership / Collaboration Program B2B service offering through which Sinopia applies the LEADS platform to identify and advance novel therapeutic targets and small-molecule candidates for biopharmaceutical partners under milestone-bearing research collaborations; demonstrated by the Ono Pharmaceutical target-discovery collaboration.
Quantifiable outcome
- Identified novel targets for multiple indications that were successfully validated in vivo
- +3 more outcomes
Companies that use Sinopia Biosciences
Customer profileSegments6 records
Ideal customer profiles3 records
Sinopia Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Sinopia Biosciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Ono Pharmaceutical Co., Ltd.coreSinopia Biosciences announced a target discovery collaboration with Ono Pharmaceutical focused on an undisclosed group of rare metabolic disorders with significant unmet medical need. Sinopia will apply its proprietary metabolomics-driven discovery platform (LEADS) to identify and validate novel therapeutic targets. Ono Pharmaceutical may advance identified targets toward development of new medicines. Sinopia will receive research funding, an upfront payment, and is eligible for future milestones.
- Omix TechnologiescoreNIGMS Phase I SBIR awarded to Sinopia Biosciences and Omix Technologies to develop a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery. The collaboration combines Sinopia's computational analysis expertise with Omix's ability to generate metabolomics data with unprecedented throughput, accuracy, and precision for applications in drug discovery, drug repurposing, and drug safety.
- San Diego Blood BankminorMulti-center collaboration for NHLBI Phase II SBIR on improving red blood cell transfusion through systems biology. The San Diego Blood Bank collaborated on testing novel additives to better preserve red blood cells for transfusion.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Sinopia Biosciences competitors and assessment
Company assessmentBroad incumbents
- Schrödinger: Computational chemistry and materials science platform with a broader drug discovery offering including software, services, and internal pipeline. Larger and more diversified than Sinopia, but overlapping in the AI/ML-meets-pharma-discovery space.
Direct peers
- BioAge Labs: AI/ML-driven biotech identifying drug targets from human aging biology data. Comparable approach to Sinopia in using proprietary omics datasets and machine learning for target identification and compound prioritization.
- Exscientia: AI-native pharma combining precision design with automated experimentation to advance small molecule drug candidates. Comparable to Sinopia in marrying AI/ML with small-molecule discovery, though Exscientia has multiple clinical-stage assets and a much larger capital base.
- Atomwise: AI-driven small molecule drug design using structure-based deep learning. Comparable to Sinopia's LEADS platform as an AI/ML drug discovery partner for pharma, with similar partnership-driven GTM motions.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutic targets. Directly comparable to Sinopia's LEADS platform in approach (data + ML for target ID) but at significantly larger scale and with clinical-stage assets.
- Insitro: Machine learning-driven drug discovery platform integrating high-throughput biology and predictive models for therapeutic discovery. Closely aligned with Sinopia's LEADS philosophy of using ML on rich biological data to uncover novel targets.
- Lantern Pharma: AI-driven precision oncology company using machine learning and multi-omics to identify and advance targeted therapies. Relevant given Sinopia's NCI-funded oncology work on cancer therapy resistance signatures.
- Verge Genomics: AI/ML platform applying machine learning to human omics data for neuroscience drug discovery. Particularly relevant given Sinopia's focus on Parkinson's disease and the shared approach of using omics-derived insights to identify CNS targets.
Emerging players
- Owkin: AI for biomedical research applying federated learning to multi-omics and clinical data for drug discovery and diagnostics. Comparable in the AI/omics-driven drug discovery space, particularly relevant to Sinopia's multi-omics integration approach.
Others
- Metabolon: Specialty metabolomics services provider enabling biomarker discovery and multi-omics research. Adjacent to Sinopia — supplies the metabolomics data infrastructure that LEADS builds upon, and a potential data-generation partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks3 records
Key highlights7 records
Customer concentration
Sinopia Biosciences social profiles
Digital presenceSinopia Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sinopia Biosciences leadership team
Management profileNumber of profiles
Profiles7 records
Sinopia Biosciences funding detail
Funding detailFunding overview
Funding rounds17 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sinopia Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sinopia Biosciences
What does Sinopia Biosciences do?
Sinopia Biosciences operates a proprietary drug-discovery platform called LEADS (LEarn And DiScover) that integrates high-throughput metabolomics data, AI/machine-learning foundation models engineered for omics, network analyses, and disease models to identify novel therapeutic targets and advance small-molecule drug candidates. Its most advanced program, SB-0110, is in clinical development for Parkinson's disease, with additional research programs spanning oral mucositis, oncology, rare blood disorders (platelet production), and rare metabolic diseases. The company monetizes this capability primarily through grant-funded research and milestone-bearing collaborations with biopharmaceutical partners such as Ono Pharmaceutical.
Is Sinopia Biosciences a public or private company?
Sinopia Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Sinopia Biosciences founded?
Sinopia Biosciences was founded in 2014. It employs 1 to 10 people.
Where is Sinopia Biosciences based?
Sinopia Biosciences is headquartered in San Diego, United States, in the North America region.
How does Sinopia Biosciences make money?
Three revenue lines are on record. Grant Funding (NIH) is the primary driver. The others are strategic Partnerships and Collaborations and future Therapeutic Development.
Who are Sinopia Biosciences's main competitors?
Schrödinger is listed as a broad incumbent. Direct peers are BioAge Labs, Exscientia, Atomwise, Recursion Pharmaceuticals, Insitro, Lantern Pharma and Verge Genomics. Owkin is listed as an emerging player. Metabolon is listed as an others.
Does Sinopia Biosciences have an API?
No public API is recorded for Sinopia Biosciences.
What industry is Sinopia Biosciences in?
Sinopia Biosciences's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.